OncoMatch/Clinical Trials/NCT05952557
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Is NCT05952557 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments for breast cancer, early breast cancer.
Treatment: Camizestrant · Tamoxifen · Anastrozole · Letrozole · Exemestane · Abemaciclib — This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Endocrine / hormonal
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) negative
Required: ESR1 positive
Disease stage
Required: Stage EARLY-STAGE
Excluded: Stage IV, INOPERABLE LOCALLY ADVANCED
early-stage resected invasive breast cancer with absence of any evidence of metastatic disease; Inoperable locally advanced or metastatic breast cancer [excluded]
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: surgery — definitive/curative
Completed adequate (definitive) locoregional therapy (surgery with or without radiotherapy) for the primary breast tumour(s)
Cannot have received: camizestrant (camizestrant)
Previous treatment with camizestrant
Cannot have received: investigational SERD
investigational SERDs/investigational ER targeting agents
Cannot have received: estrogen receptor antagonist (fulvestrant)
fulvestrant
Lab requirements
Blood counts
Adequate organ and bone marrow function
Kidney function
Adequate organ and bone marrow function
Liver function
Adequate organ and bone marrow function
Cardiac function
Known LVEF <50% with heart failure NYHA Grade ≥2 [excluded]; Mean resting QTcF interval > 480 ms at screening [excluded]
Adequate organ and bone marrow function; Known LVEF <50% with heart failure NYHA Grade ≥2 [excluded]; Mean resting QTcF interval > 480 ms at screening [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Dothan, Alabama
- Research Site · Phoenix, Arizona
- Research Site · Tucson, Arizona
- Research Site · Fayetteville, Arkansas
- Research Site · Duarte, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05952557 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior camizestrant, investigational SERD, estrogen receptor antagonist disqualifies patients from enrollment.
Does this trial require ERBB2?
Yes, ERBB2 negative is a required biomarker for enrollment.
Does this trial require ESR1?
Yes, ESR1 positive is a required biomarker for enrollment.
What disease stage is eligible?
Stage EARLY-STAGE is required.
Is there an age limit?
Yes. Patients must be 130 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages